"Reimbursement is a series of hurdles; it's a marathon."
- Roger Longman, CEO of consulting firm Real Endpoints LLC
"The success of the company going forward is going to be driven by many things – none more important than denosumab."
- Amgen Inc. CEO Kevin Sharer, during a recent business update
"While it could be that Dendreon's explanations ultimately prove true, and that Provenge's ramp is simply delayed, we are tired of making excuses for what has been a disappointing commercial trajectory since day 1 of launch."
- Eric Schmidt, analyst with Cowen and Co., on Dendreon Corp.'s second-quarter miss